This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Charles River Laboratories International In (CRL)

NYSE: Health Care

Company Income Statement
Dec 2015 Dec 2014 Dec 2013 Dec 2012
Sales 1.36B 1.30B 1.17B 1.13B
Cost of Sales 759.18M 752.79M 678.03M 653.07M
Gross Operating Profit 604.12M 544.87M 487.50M 476.46M
Selling, General, and Administrative Expenses 300.41M 269.03M 225.69M 208.25M
Research & Development 0.00 0.00 0.00 0.00
Operating Income before D & A (EBITDA) 303.71M 275.84M 261.80M 268.21M
Depreciation & Amortization 97.26M 98.17M 106.20M 98.90M
Interest Income 1.04M 1.15M 730.00K 589.00K
Other Income - Net 3.01M 10.72M 7.17M -3.27M
Special Income / Charges 0.00 0.00 -4.20M -3.55M
Total Income Before Interest Expenses (EBIT) 210.50M 189.54M 159.30M 163.09M
Interest Expense 15.07M 11.95M 20.97M 33.34M
Pre-Tax Income 195.43M 177.59M 138.33M 129.75M
Income Taxes 43.39M 47.67M 32.91M 27.63M
Minority Interest 1.77M 1.50M 1.32M 571.00K
Net Income From Continuing Operations 152.04M 129.92M 105.42M 102.12M
Net Income From Discontinued Operations -950.00K -1.73M -1.26M -4.25M
Net Income From Total Operations 151.09M 128.20M 104.15M 97.87M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 149.31M 126.70M 102.83M 97.30M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
152.04M 129.92M 109.62M 105.67M
Preferred Dividends
Net Income Available To Common 152.04M 129.92M 105.42M 102.12M
Basic EPS from Continuing Ops. 3.23 2.76 2.18 2.12
Basic EPS from Discontinued Ops. -0.02 -0.04 -0.03 -0.09
Basic EPS from Total Operations 3.21 2.72 2.15 2.03
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 3.21 2.72 2.15 2.03
Basic Normalized Net Income/Share 3.23 2.76 2.27 2.19
EPS fr Continuing Ops. 3.15 2.70 2.15 2.10
EPS fr Discontinued Ops -0.02 -0.04 -0.03 -0.09
EPS fr Total Ops. 3.13 2.66 2.12 2.01
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total 3.13 2.66 2.12 2.01
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
3.15 2.70 2.24 2.17
Dividends Paid per Share 0.00 0.00 0.00 0.00
CRL News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

CRL Charles River Laboratories International In

Chart of CRL

Analysts Ratings for CRL

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 8 7 7 7
Moderate Buy 0 0 0 0
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
GET CRL ANALYST REPORT

CRL Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs